ADMA (ADMA Biologics) Interest Expense : $-13.9 Mil (TTM As of Dec. 2024)

View and export this data going back to 2013. Start your Free Trial

What is ADMA Biologics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. ADMA Biologics's interest expense for the three months ended in Dec. 2024 was $ -2.9 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2024 was $-13.9 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. ADMA Biologics's Operating Income for the three months ended in Dec. 2024 was $ 38.3 Mil. ADMA Biologics's Interest Expense for the three months ended in Dec. 2024 was $ -2.9 Mil. ADMA Biologics's Interest Coverage for the quarter that ended in Dec. 2024 was 13.31. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

ADMA Biologics Interest Expense Historical Data

The historical data trend for ADMA Biologics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ADMA Biologics Interest Expense Chart

ADMA Biologics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Expense

Get a 7-Day Free Trial

-11.99

-13.06

-19.28

-25.03

-13.93

ADMA Biologics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Interest Expense	Get a 7-Day Free Trial															-6.22	-3.77	-3.78	-3.50	-2.88

ADMA Biologics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-13.9 Mil.

ADMA Biologics (NAS:ADMA) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

ADMA Biologics's Interest Expense for the three months ended in Dec. 2024 was $-2.9 Mil. Its Operating Income for the three months ended in Dec. 2024 was $38.3 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2024 was $80.9 Mil.

ADMA Biologics's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Dec. 2024 )	/	Interest Expense (Q: Dec. 2024 )
	=	-1	*	38.323	/	-2.879
	=	13.31

The higher the ratio, the stronger the company's financial strength is.

ADMA Biologics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ADMA Biologics Inc (NAS:ADMA) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

465 State Route 17, Ramsey, NJ, USA, 07446

Website

https://www.admabiologics.com

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.

Executives

Adam S Grossman	director, officer: President and CEO	65 COMMERCE WAY, HACKENSACK NJ 07601
Lawrence P. Guiheen	director	65 COMMERCE WAY, HACKENSACK NJ 07601
Jerrold B Grossman	director	65 COMMERCE WAY, HACKENSACK NJ 07601
Young Kwon	director	C/O MOMENTA PHARMACEUTICALS INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Steve Elms	director	888 SEVENTH AVE, 29TH FL, NEW YORK NY 10106
Alison Cecily Finger	director	C/O BLUEBIRD BIO, INC., 60 BINNEY STREET, CAMBRIDGE MA 02142
Bryant Fong	director	2170 VALLEJO STREET #101, SAN FRANCISCO CA 94123
Brian Lenz	officer: EVP, CFO	65 COMMERCE WAY, HACKENSACK NJ 07601
Martha J Demski	director	7770 REGENTS ROAD SUITE 113-505, SAN DIEGO CA 92122
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
James Mond	officer: CSO/CMO	65 COMMERCE WAY, HACKENSACK NJ 07601
Biotest Divestiture Trust	10 percent owner	C/O ERIC ROSENBACH, TRUSTEE, 402 NORFOLK STREET, CAMBRIDGE MA 02139
Perceptive Advisors Llc	10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Eric I Richman	director	C/O REV CAPITAL II, LLC, 9740 SORREL AVE, POTOMAC MD 20854